Peer-reviewed papers

  1.  Notarbartolo-di-Sciara GN, Hillyer EV. Mobulid rays off eastern Venezuela (Chondrichthyes, Mobulidae). Copeia 1989;(3):607-614.
    Journal Website
  2. Hillyer EV, Moroff S, Hoefer H, Quesenberry KE. Bile duct carcinoma in two out of ten Amazon parrots with cloacal papillomas. J Assoc Avian Vet 1991;5:91-95. Journal Website
  3. Hillyer EV, Anderson MP, Greiner EC, Atkinson CT, Frenkel JK. An outbreak of Sarcocystis in a collection of psittacines. J Zoo Wildl Med 1991;22:434-445. Journal Website
  4. Mullen HS, Scavelli TD, Quesenberry KE, Hillyer E. Gastrointestinal foreign body in ferrets: 25 cases (1986 to 1990). J Amer An Hosp Assoc 1992;28:13-19. Journal Website
  5. Rosenthal K, Hillyer E, Mathiessen D. Stifle luxation repair in a Moluccan cockatoo and a barn owl. J Assoc Avian Vet 1992;6:235-238. Journal Website
  6. Rosenthal KL, Peterson ME, Quesenberry KE, Hillyer EV, Beeber NL, Moroff SD, Lothrop CD, Jr. Hyperadrenocorticism associated with adrenocortical tumor or nodular hyperplasia of the adrenal gland in ferrets: 50 cases (1987-1991). J Am Vet Med Assoc 1993;203:271-275. PubMed Link
  7. Blanco MC, Fox JG, Rosenthal K, Hillyer EV, Quesenberry KE, Murphy JC. Megaesophagus in nine ferrets. J Am Vet Med Assoc 1994;205:444-447. PubMed Link
  8. Hand R, Liberti LE, Hillyer EV, Goscinsky L. A review of the pharmacology, clinical applications, and toxicology of hirudin and Hirulog™. Transgenica 1994;1:1-22.
  9. Dueland AN, Leira R, Burke TA, Hillyer EV, Bolge S. The impact of migraine on work, family, and leisure among young women – a multinational study. Curr Med Res Opin 2004;20:1595-1604. PubMed Link
  10. Panettieri RA, Jr., Covar R, Grant E, Hillyer EV, Bacharier L. Natural history of asthma: persistence versus progression-does the beginning predict the end? J Allergy Clin Immunol 2008;121:607-613. PubMed Link
  11. Haughney J, Price D, Kaplan A, Chrystyn H, Horne R, May N, Moffat M, Versnel J, Shanahan ER, Hillyer EV, Tunsater A, Bjermer L. Achieving asthma control in practice: understanding the reasons for poor control. Respir Med 2008;102:1681-1693. PubMed Link
  12. Thomas M, Kay S, Pike J, Williams A, Rosenzweig JR, Hillyer EV, Price D. The Asthma Control Test (ACT) as a predictor of GINA guideline-defined asthma control: analysis of a multinational cross-sectional survey. Prim Care Respir J 2009;18:41-49. PubMed Link
  13. Wilson EC, Price D, Musgrave SD, Sims EJ, Shepstone L, Murdoch J, Mugford HM, Blyth A, Juniper EF, Ayres JG, Wolfe S, Freeman D, Gilbert RF, Hillyer EV, Harvey I. Cost effectiveness of leukotriene receptor antagonists versus long-acting beta-2 agonists as add-on therapy to inhaled corticosteroids for asthma: a pragmatic trial. Pharmacoeconomics 2010;28:597-608. PubMedLink
  14. Wilson EC, Sims EJ, Musgrave SD, Shepstone L, Blyth A, Murdoch J, Mugford HM, Juniper EF, Ayres JG, Wolfe S, Freeman D, Gilbert RF, Harvey I, Hillyer EV, Price D. Cost effectiveness of leukotriene receptor antagonists versus inhaled corticosteroids for initial asthma controller therapy: a pragmatic trial. Pharmacoeconomics 2010;28:585-595. PubMed Link
  15. Price D, Kemp L, Sims E, von Ziegenweidt J, Navaratnam P, Lee AJ, Chisholm A, Hillyer EV, Gopalan G. Observational study comparing intranasal mometasone furoate with oral antihistamines for rhinitis and asthma. Prim Care Respir J 2010;19:266-273. PubMed Link
  16. Price D, Martin RJ, Barnes N, Dorinsky P, Israel E, Roche N, Chisholm A, Hillyer EV, Kemp L, Lee AJ, von Ziegenweidt J, Colice G. Prescribing practices and asthma control with hydrofluoroalkane-beclomethasone and fluticasone: a real-world observational study. J Allergy Clin Immunol 2010;126:511-518. e1-10. PubMed Link
  17. Kemp L, Haughney J, Barnes N, Sims E, von Ziegenweidt J, Hillyer EV, Lee AJ, Chisholm A, Price D. Cost-effectiveness analysis of corticosteroid inhaler devices in primary care asthma management: A real world observational study. ClinicoEconomics Outcomes Res 2010;2:75-85. PubMed Link
  18. Barnes N, Price D, Colice G, Chisholm A, Dorinsky P, Hillyer EV, Burden A, Lee AJ, Martin RJ, Roche N, von Ziegenweidt J, Israel E. Asthma control with extrafine-particle hydrofluoroalkane-beclometasone vs. large-particle chlorofluorocarbon-beclometasone: a real-world observational study. Clin Exp Allergy 2011;41:1521-1532. PubMed Link
  19. Price D, Chisholm A, van der Molen T, Roche N, Hillyer EV, Bousquet J. Reassessing the evidence hierarchy in asthma: evaluating comparative effectiveness. Curr Allergy Asthma Rep 2011;11:526-538. PubMed Link
  20. Price D, Haughney J, Sims E, Ali M, von Ziegenweidt J, Hillyer EV, Lee AJ, Chisholm A, Barnes N. Effectiveness of inhaler types for real-world asthma management: retrospective observational study using the GPRD. J Asthma Allergy 2011;4:37-47. PubMed Link
  21. Price D, Roche N, Christian Virchow J, Burden A, Ali M, Chisholm A, Lee AJ, Hillyer EV, von Ziegenweidt J. Device type and real-world effectiveness of asthma combination therapy: An observational study. Respir Med 2011;105:1457-1466. PubMed Link
  22. Price D, Musgrave SD, Shepstone L, Hillyer EV, Sims EJ, Gilbert RF, Juniper EF, Ayres JG, Kemp L, Blyth A, Wilson EC, Wolfe S, Freeman D, Mugford HM, Murdoch J, Harvey I. Leukotriene antagonists as first-line or add-on asthma-controller therapy. N Engl J Med 2011;364:1695-1707. PubMed Link
  23. Price D, Roche N, Christian Virchow J, Burden A, Ali M, Chisholm A, Lee AJ, Hillyer EV, von Ziegenweidt J. Device type and real-world effectiveness of asthma combination therapy: An observational study. Respir Med 2011;105:1457-1466. PubMed Link
  24. Price D, Chrystyn H, Kaplan A, Haughney J, Roman-Rodriguez M, Burden A, Chisholm A, Hillyer EV, von Ziegenweidt J, Ali M, van der Molen T. Effectiveness of same versus mixed asthma inhaler devices: a retrospective observational study in primary care. Allergy Asthma Immunol Res 2012;4:184-191. PubMed Link
  25. Colice G, Martin RJ, Israel E, Roche N, Barnes N, Burden A, Polos P, Dorinsky P, Hillyer EV, Lee AJ, Chisholm A, von Ziegenweidt J, Barion F, Price D. Asthma outcomes and costs of therapy with extrafine beclomethasone and fluticasone. J Allergy Clin Immunol 2013;132:45-54 e10. PubMed Link
  26. Price D, Hillyer EV, van der Molen T. Efficacy versus effectiveness trials: informing guidelines for asthma management. Curr Opin Allergy Clin Immunol 2013;13:50-57. PubMed Link
  27. Price D, Thomas M, Haughney J, Lewis RA, Burden A, von Ziegenweidt J, Chisholm A, Hillyer EV, Corrigan CJ. Real-life comparison of beclometasone dipropionate as an extrafine- or larger-particle formulation for asthma. Respir Med 2013;107:987-1000. PubMed Link
  28. Price D, Lee AJ, Sims EJ, Kemp L, Hillyer EV, Chisholm A, von Ziegenweidt J, Williams A. Characteristics of patients preferring once-daily controller therapy for asthma and COPD: a retrospective cohort study. Prim Care Respir J 2013;22:161-168. PubMed Link
  29. Price D, Hillyer EV. Fluticasone propionate/formoterol fumarate in fixed-dose combination for the treatment of asthma. Expert Rev Respir Med 2014;8:275-291. PubMed Link
  30. Postma DS, Roche N, Colice G, Israel E, Martin RJ, van Aalderen WM, Grigg J, Burden A, Hillyer EV, von Ziegenweidt J, Gopalan G, Price D. Comparing the effectiveness of small-particle versus large-particle inhaled corticosteroid in COPD. Int J Chron Obstruct Pulmon Dis 2014;9:1163-1186. PubMed Link
  31. Martin RJ, Price D, Roche N, Israel E, van Aalderen WM, Grigg J, Postma DS, Guilbert TW, Hillyer EV, Burden A, von Ziegenweidt J, Colice G. Cost-effectiveness of initiating extrafine- or standard size-particle inhaled corticosteroid for asthma in two health-care systems: a retrospective matched cohort study. NPJ Prim Care Respir Med 2014;24:14081. PubMed Link
  32. Price D, Bateman ED, Chisholm A, Papadopoulos NG, Bosnic-Anticevich S, Pizzichini E, Hillyer EV, Buist AS. Complementing the randomized controlled trial evidence base. Evolution not revolution. Ann Am Thorac Soc 2014;11 Suppl 2:S92-98. PubMed Link
  33. Roche N, Postma DS, Colice G, Burden A, Guilbert TW, Israel E, Martin RJ, van Aalderen WM, Grigg J, Hillyer EV, von Ziegenweidt J, Price DB. Differential effects of inhaled corticosteroids in smokers/ex-smokers and nonsmokers with asthma. Am J Respir Crit Care Med 2015;191:960-964. PubMed Link
  34. Israel E, Roche N, Martin RJ, Colice G, Dorinsky PM, Postma DS, Guilbert TW, van Aalderen WM, Grigg J, Hillyer EV, Burden A, von Ziegenweidt J, Thomas V, Price DB. Increased dose of inhaled corticosteroid vs. add-on long-acting beta-agonist for step-up therapy in asthma. Ann Am Thorac Soc 2015;12:798-806. PubMed Link
  35. van Aalderen WM, Grigg J, Guilbert TW, Roche N, Israel E, Martin RJ, Colice G, Postma DS, Hillyer EV, Burden A, Thomas V, von Ziegenweidt J, Price D. Small-particle inhaled corticosteroid as first-line or step-up controller therapy in childhood asthma. J Allergy Clin Immunol Pract 2015;3:721-731, e16. PubMed Link
  36. Price DB, Rigazio A, Campbell JD, Bleecker ER, Corrigan CJ, Thomas M, Wenzel SE, Wilson AM, Small MB, Gopalan G, Ashton VL, Burden A, Hillyer EV, Kerkhof M, Pavord ID. Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study. Lancet Respir Med 2015;3:849-858. PubMed Link
  37. Roche N, Colice G, Israel E, Martin RJ, Dorinsky PM, Postma DS, Guilbert TW, Grigg J, van Aalderen WMC, Barion F, Hillyer EV, Thomas V, Burden A, McQueen RB, Price DB. Cost-effectiveness of asthma step-up therapy as an increased dose of extrafine-particle inhaled corticosteroid or add-on long-acting beta2-agonist. Pulm Ther 2016;2:73-89. Journal Website
  38. van der Molen T, Postma DS, Martin RJ, Herings RM, Overbeek JA, Thomas V, Miglio C, Dekhuijzen R, Roche N, Guilbert T, Israel E, van Aalderen W, Hillyer EV, van Rysewyk S, Price DB. Effectiveness of initiating extrafine-particle versus fine-particle inhaled corticosteroids as asthma therapy in the Netherlands. BMC Pulm Med 2016;16:80. PubMed Link
  39. Turner S, Richardson K, Murray C, Thomas M, Hillyer EV, Burden A, Price DB. Long-acting beta-agonist in combination or separate inhaler as step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids. J Allergy Clin Immunol Pract 2017;5:99-106 e103. PubMed Link
  40. Postma DS, Dekhuijzen R, van der Molen T, Martin RJ, van Aalderen W, Roche N, Guilbert TW, Israel E, van Eickels D, Khalid JM, Herings RM, Overbeek JA, Miglio C, Thomas V, Hutton C, Hillyer EV, Price DB. Asthma-related outcomes in patients initiating extrafine ciclesonide or fine-particle inhaled corticosteroids. Allergy Asthma Immunol Res 2017;9:116-125. PubMed Link
  41. Price DB, Colice G, Israel E, Roche N, Postma DS, Guilbert TW, van Aalderen WM, Grigg J, Hillyer EV, Thomas V, Martin RJ. Add-on LABA in a separate inhaler as asthma step-up therapy versus increased dose of ICS or ICS/LABA combination inhaler. ERJ Open Res 2016;2:00106-02015. PubMed Link
  42. Burden A, Roche N, Miglio C, Hillyer EV, Postma DS, Herings RMC, Overbeek JA, Khalid JM, van Eickels D, Price DB. An evaluation of exact matching and propensity score methods as applied in a comparative effectiveness study of inhaled corticosteroids in asthma. Pragmatic Obs Res 2017;8:15-30. PubMed Link
  43. Guilbert TW, Colice G, Grigg J, van Aalderen W, Martin RJ, Israel E, Postma DS, Roche N, Phipatanakul W, Hillyer EV, Evans JM, Dolovich MB, Price DB. Real-life outcomes for patients with asthma prescribed spacers for use with either extrafine- or fine-particle inhaled corticosteroids. J Allergy Clin Immunol Pract 2017;5:1040-1049 e1044. PubMed Link
  44. Postma DS, Kaplan A, Soriano JB, Grigg J, Guilbert TW, van Aalderen W, Roche N, Burden A, Hillyer EV, Israel E, Price DB. Cohort analysis of exacerbation rates in adolescent and adult patients initiating inhaled corticosteroids for asthma: different dose–response profile by particle size. Pulm Ther. 2017;3:113-124. Journal Website
  45. Kerkhof M, Sonnappa S, Postma DS, Brusselle G, Agusti A, Anzueto A, Jones R, Papi A, Pavord I, Pizzichini E, Popov T, Roche N, Ryan D, Thomas M, Vogelmeier C, Chisholm A, Freeman D, Bafadhel M, Hillyer EV, Price DB. Blood eosinophil count and exacerbation risk in patients with COPD. Eur Respir J. 2017;50. PubMed Link
  46. Blakey JD, Price DB, Pizzichini E, Popov TA, Dimitrov BD, Postma DS, Josephs LK, Kaplan A, Papi A, Kerkhof M, Hillyer EV, Chisholm A, Thomas M. Identifying risk of future asthma attacks using UK medical record data: A Respiratory Effectiveness Group initiative. J Allergy Clin Immunol Pract. 2017;5:1015-1024 e1018. PubMed Link
  47. Hillyer EV, Price DB, Chrystyn H, Martin RJ, Israel E, van Aalderen WMC, Papi A, Usmani OS, Roche N. Harmonizing the nomenclature for therapeutic aerosol particle size: a proposal. J Aerosol Med Pulm Drug Deliv. 2018;31:111-113. PubMed Link
  48. Kerkhof M, Tran TN, Soriano JB, Golam S, Gibson D, Hillyer EV, Price DB. Healthcare resource use and costs of severe, uncontrolled eosinophilic asthma in the UK general population. Thorax. 2018;73:116-124. PubMed Link